X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES SANOFI INDIA JUBILANT LIFE SCIENCES/
SANOFI INDIA
 
P/E (TTM) x 15.4 38.2 40.4% View Chart
P/BV x 4.6 7.2 63.2% View Chart
Dividend Yield % 0.4 0.5 75.8%  

Financials

 JUBILANT LIFE SCIENCES   SANOFI INDIA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
SANOFI INDIA
Dec-17
JUBILANT LIFE SCIENCES/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1874,945 3.8%   
Low Rs653,901 1.7%   
Sales per share (Unadj.) Rs364.31,081.8 33.7%  
Earnings per share (Unadj.) Rs6.8141.6 4.8%  
Cash flow per share (Unadj.) Rs24.5185.9 13.2%  
Dividends per share (Unadj.) Rs3.0033.00 9.1%  
Dividend yield (eoy) %2.40.7 319.2%  
Book value per share (Unadj.) Rs164.9868.8 19.0%  
Shares outstanding (eoy) m159.2823.03 691.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.1 8.5%   
Avg P/E ratio x18.431.2 58.9%  
P/CF ratio (eoy) x5.123.8 21.6%  
Price / Book Value ratio x0.85.1 15.0%  
Dividend payout %43.823.3 188.0%   
Avg Mkt Cap Rs m20,061101,862 19.7%   
No. of employees `0006.23.2 191.0%   
Total wages/salary Rs m11,0523,685 299.9%   
Avg. sales/employee Rs Th9,383.07,691.9 122.0%   
Avg. wages/employee Rs Th1,786.91,137.7 157.1%   
Avg. net profit/employee Rs Th176.31,006.5 17.5%   
INCOME DATA
Net Sales Rs m58,03424,914 232.9%  
Other income Rs m191807 23.6%   
Total revenues Rs m58,22425,721 226.4%   
Gross profit Rs m5,7865,372 107.7%  
Depreciation Rs m2,8121,022 275.1%   
Interest Rs m3,23711 29,429.1%   
Profit before tax Rs m-725,146 -1.4%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m6961,886 36.9%   
Profit after tax Rs m1,0903,260 33.4%  
Gross profit margin %10.021.6 46.2%  
Effective tax rate %-965.936.6 -2,635.4%   
Net profit margin %1.913.1 14.4%  
BALANCE SHEET DATA
Current assets Rs m29,28014,432 202.9%   
Current liabilities Rs m38,9126,010 647.4%   
Net working cap to sales %-16.633.8 -49.1%  
Current ratio x0.82.4 31.3%  
Inventory Days Days8461 138.6%  
Debtors Days Days5128 178.0%  
Net fixed assets Rs m55,7127,991 697.2%   
Share capital Rs m155230 67.1%   
"Free" reserves Rs m20,96819,778 106.0%   
Net worth Rs m26,26520,008 131.3%   
Long term debt Rs m17,1690-   
Total assets Rs m88,60627,770 319.1%  
Interest coverage x1.0468.8 0.2%   
Debt to equity ratio x0.70-  
Sales to assets ratio x0.70.9 73.0%   
Return on assets %4.911.8 41.5%  
Return on equity %4.216.3 25.5%  
Return on capital %11.625.8 44.9%  
Exports to sales %37.80-   
Imports to sales %16.50-   
Exports (fob) Rs m21,933NA-   
Imports (cif) Rs m9,567NA-   
Fx inflow Rs m22,0046,306 348.9%   
Fx outflow Rs m11,7495,257 223.5%   
Net fx Rs m10,2551,049 977.6%   
CASH FLOW
From Operations Rs m8,0264,351 184.5%  
From Investments Rs m-1,744-787 221.6%  
From Financial Activity Rs m-4,447-1,884 236.1%  
Net Cashflow Rs m1,8341,680 109.2%  

Share Holding

Indian Promoters % 45.6 0.0 -  
Foreign collaborators % 3.5 60.4 5.8%  
Indian inst/Mut Fund % 8.7 14.4 60.4%  
FIIs % 21.2 14.6 145.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 10.5 201.0%  
Shareholders   23,815 15,184 156.8%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   VENUS REMEDIES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY19); Net Profit Up 67.2% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 67.2% YoY). Sales on the other hand came in at Rs 23 bn (up 38.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY18); Net Profit Up 37.5% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SANOFI INDIA has posted a net profit of Rs 825 m (up 37.5% YoY). Sales on the other hand came in at Rs 6 bn (up 11.7% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Dec 12, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - GLENMARK PHARMA COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS